Today: 20 March 2026
Arm stock edges higher as Fed minutes steer year-end tech trade — what investors watch next
31 December 2025
1 min read

Arm stock edges higher as Fed minutes steer year-end tech trade — what investors watch next

NEW YORK, December 30, 2025, 23:11 ET — Market closed

  • Arm Holdings’ sponsored ADRs closed at $110.86, up $0.35 (0.32%). MarketWatch
  • U.S. stocks ended slightly lower in holiday-thin trading as investors parsed Federal Reserve minutes and rotated within mega-cap tech. Reuters+1
  • Next catalysts include Wednesday’s final session of 2025 and Arm’s tentative Feb. 4 earnings date. Arm Investors

Arm Holdings’ U.S.-listed sponsored ADRs (ARM.O) ended Tuesday up 0.32% at $110.86, a small gain in a choppy session that left the broader market slightly lower. MarketWatch+1

The muted move matters now because investors are recalibrating rate-sensitive growth exposure into year-end, after minutes from the Federal Reserve’s December meeting highlighted unusually sharp divisions over the path of policy. Reuters

For Arm, the next clear company catalyst is earnings. Arm’s investor relations calendar lists Feb. 4, 2026 as a tentative date for its fiscal third-quarter results, a report investors will use to gauge licensing and royalty momentum tied to AI data centers and smartphones. Arm Investors

MarketWatch data showed Arm gained $0.35 from a previous close of $110.51. The stock traded between $110.39 and $112.00, with roughly 3.6 million shares changing hands, according to market data compiled by Investing.com. MarketWatch+1

On Wall Street, the S&P 500 slipped 0.14% and the Nasdaq Composite fell 0.23% as gains in communication services were offset by weakness in technology and financials, Reuters reported. Reuters

Mega-cap signals were mixed, with Apple down 0.3% and Nvidia off 0.4%, while Meta rose after it said it would buy AI startup Manus, according to Reuters. Reuters

“It’s just a healthy rebalancing of allocations,” Mark Hackett, chief market strategist at Nationwide, said, describing the shift in tech positioning. Reuters

Arm’s ADRs trade in the U.S. as depositary receipts — a U.S.-listed certificate that represents shares of a foreign company — and the stock often moves with the broader “AI trade” even though Arm sells chip designs rather than manufacturing chips. Reuters

Arm generates revenue from upfront licensing fees for its processor designs and royalties — a per-chip fee collected when customers ship products built on Arm technology — putting investor focus on the pace of adoption and pricing power. Reuters

Before the next session, traders will be watching whether thin holiday liquidity continues to amplify sector rotations, a dynamic Reuters said has kept volatility elevated despite small index moves. Reuters

Investors are also looking ahead to the Fed’s Jan. 27–28 meeting, after the minutes showed some officials viewed the December rate cut as “finely balanced” and debated how long to stay on hold. Reuters+1

Technically, Arm heads into Wednesday near $111, close to the lower end of its 52-week range of $80.00 to $183.16. A push above Tuesday’s $112 intraday high would be an early hurdle, while the $110 area has been the nearest support in recent sessions. Investing.com+1

With no fresh Arm-specific catalyst driving Tuesday’s tape, the stock is likely to stay tethered to rate expectations and risk appetite until the next earnings update sharpens the outlook on licensing and royalties. Reuters+1

Stock Market Today

  • BioMarin Pharmaceutical Q4 Earnings Lag Peers in Therapeutics Sector
    March 20, 2026, 4:06 PM EDT. BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q4 revenues of $874.6 million, a 17% year-on-year increase, beating expectations by 4.8%. However, the company missed full-year earnings per share (EPS) guidance and offered the weakest outlook among its therapeutics peers, causing its stock to tumble 12% to $55.37. Therapeutics stocks overall showed strong performance, beating revenue estimates by 7.1% on average and holding steady post-earnings. Novavax (NASDAQ:NVAX) led the pack with 66.6% revenue growth, surpassing estimates by 57.4%, driving its stock up 2.4% to $9.76. While BioMarin faces challenges including regulatory scrutiny and competition, advancements in precision medicine and rare disease demand boost the sector. Investors watch for operational execution and pipeline progress amid mixed signals.
Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh
Previous Story

Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh

ConocoPhillips stock rises as oil steadies; Australia gas well update and Feb. 5 earnings in focus
Next Story

ConocoPhillips stock rises as oil steadies; Australia gas well update and Feb. 5 earnings in focus

Go toTop